It's been a good month. The M&A deal yesterday got Cramer all cranked up on mid-size/deal size biotech again, so he's sure to be pumping all week. Shorts are running like #$%$ a roaches in the daylight. For the spelling police, that was an intentional misspelling. Tony Montana.
unless they get some help in the form of bad news, shorts have no way of buying 25MM shares without causing a major price increase. They are trapped. Ring ring, mr. shorty we are calling your shares in, you must buy and cover within 3 days...
Looks like the Sept 27 calls and Jan 25's were both new buys, OI increased for both. $4 in 25 days, Hmmm. I noticed Cramer is planning to pump up biotech all week, not good news for the bio-shorts.
Carol.Hausner is the person responsible, or irresponsible depending on your opinion. Apparently she's too busy assisting the business development department with their 3-year vacations. Perhaps she could train her assistant to do internet updating. She may be too busy fending off angry shareholders who are tired of losing money.
Roche owns the cow and is getting the milk for 3-5 cents on the dollar and managing their Her2 franchise to max profits for Roche. I think Sanofi is a more likely buyer, but they also get the milk real cheap, so maybe we will have to wait for NVS, or a breakthrough in the slowly developing pipeline. POS can't break through $12, still a lot of sellers that want out thanks to bad management of the good platform and technology.
Compared to their acquisition value in a competitive bid situation. ITMN was a $12 stock not long ago. Of course, the company must own a valuable asset to get top value. Hoping for the best here!
I agree, premium is not worth the risk of missing a potential deal, not that I think IMGN execs have any interest in selling. CH, I believe covered call selling is allowed in 401k plans. Glad, so far, I sold my extra IMGN shares and bought EXAS. I got a tax loss and a nice gain so far. I do think this POS will eventually increase in spite of management's incompetence, it's just a matter of time. ITMN was a crappy $12 not long ago. Same thing could happen here with some new clinical success and openness to sell by execs and the BOD. Not giving up, planning to keep up the pressure, but not over-allocating again due to issues mentioned by CH, incompetent management and price concerns. I do think Sanofi or NVS will buy them at some point.
SAR 3419 abstract 8506 an ASCO best of for the phase II trial. IMGN execs are apparently boycotting their shareholders and trying to min shareholder value and the stock price. Flippin morons!!!
Apparently that's not news worthy, or the entire company is on vacation. It's difficult to know what they are doing. Maybe this will earn then a small milestone payment. Back to vacation now while the stock price craters.
every time I hear, or say this, it never works out quite as expected. Let's tone it down a little please. We all hope for a big winner, but in this industry risk is high and there are no guarantees of success.
doubtful on all accounts. If IMGN was larger it would be an Icahn value investment. We need an Icahn, not a Buffet. EXAS is up up and away (so far).
I think a lot of those calls will be going out soon, forced liquidation, time to cover, can't spare a share. Shorts must be carping in their pants (pun and misspelling intended).
there's no scooping necessary, I believe the product catches the necessary sample before it hits the water.
$19.05, nearing escape velocity.
I don't see any synergy between Allergan and Salix. Salix looks overbought, a good put buy or put spread candidate to me. IMO of course.